Abstract:
This is an analytical case control study which conducted in Khartoum state in the
period from October 2018 to January 2019 to evaluate the antithrombin III in
Sudanese patients with myocardial infarction (MI). For this purpose 70
individuals were chosen (40 patients with Myocardial infarction which
considered as cases and 30 healthy persons and considered as controls).
One ml point eight of fresh venous blood were collected from each volunteer
after filling the non-self questionnaire, in vacutainer tube containing 0.2 ml from
3.2% tri-sodium citrate solution for anticoagulation. Then the content of the tube
were mixed and centrifuged at 3000 round/min for 15 minutes for preparation of
platelet poor plasma (PPP). The PPP were tested for Antithrombin III by using
fully automated Biosystem device (A15). The results were analyzed by
independent T-test and one way anova of the SPSS computer programme.
The result showed that there was significant decreased ATIII level in patients
with MI (15.442 mg/dl) when compared with healthy individuals (27.840 mg/dl)
(P.value 0.000).
There was insignificant increased ATIII level in males (22.208 mg/dl) when
compared with females (18.929 mg/dl) (P. value 0.237).
Also there was insignificant increased ATIII in MI patients with diabetes
mellitus when compared with MI patients without D.M (P. value 0.782).
Also insignificant increased ATIII in MI patients with hypertension when
compared with MI patients without hypertension (P. value 0.885).
There was significant different in the level of ATIII between different age groups
(P. value 0.029).
